Overview

Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves

Status:
Unknown status
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
After implantation of an Ahmed glaucoma valve in patients with glaucoma, hyperencapsulation phase is an unwanted postoperative phenomenon, typically occurring with the free 3 months postoperatively. When this does occur, it is treated with aqueous suppressant eye drops. This study aims to determine if it is possible to reduce the rate of hyperencapsulation phase. Patients in the treatment group will receive aqueous suppressant eye drops before the hyperencapsulation phase starts. Treatment will be initiated once their intraocular pressure is above a pre-defined level, and will target a pre-defined range.
Phase:
Phase 4
Details
Lead Sponsor:
Credit Valley EyeCare
Collaborator:
Canadian Glaucoma Clinical Research Council
Treatments:
Brimonidine Tartrate
Carbonic Anhydrase Inhibitors
Ophthalmic Solutions
Tetrahydrozoline
Travoprost